Biostax Corp.
Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset,… Read more
Biostax Corp. (BTAX) - Total Liabilities
Latest total liabilities as of March 2025: $5.33 Million USD
Based on the latest financial reports, Biostax Corp. (BTAX) has total liabilities worth $5.33 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biostax Corp. - Total Liabilities Trend (2019–2023)
This chart illustrates how Biostax Corp.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biostax Corp. Competitors by Total Liabilities
The table below lists competitors of Biostax Corp. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kodal Minerals PLC
LSE:KOD
|
UK | GBX208.32K |
|
PowerUp Acquisition Corp. Warrant
NASDAQ:PWUPW
|
USA | $6.57 Million |
|
Kukyoung G&M
KO:006050
|
Korea | ₩22.83 Billion |
|
N.W.F Group
LSE:NWF
|
UK | GBX182.60 Million |
|
Voyager Digital Ltd
PINK:VYGVQ
|
USA | $5.74 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Biostax Corp.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 968.99 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biostax Corp.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biostax Corp. (2019–2023)
The table below shows the annual total liabilities of Biostax Corp. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $4.56 Million | +31.23% |
| 2022-12-31 | $3.48 Million | -68.64% |
| 2021-12-31 | $11.09 Million | -5.05% |
| 2020-12-31 | $11.68 Million | -14.73% |
| 2019-12-31 | $13.69 Million | -- |